دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Patient engagement with the BJD: encouraging the patient voice and readership
Olivia Hughes, Laura Prescott, Bernd W.M. Arents
doi : 10.1111/bjd.21812
The British Journal of Dermatology (BJD) is currently ranked among the top three dermatology journals worldwide, with a recent increase in impact factor from 9·3 in 2021 to 11·1 in 2022.
Psoriasis treatment: no more room on the summit?
LluÃs Puig
doi : 10.1111/bjd.21848
The article by Blauvelt et al., published in this issue of the BJD, is an excellent illustration of the current state of the art in randomized clinical trial design and drug development for moderate-to-severe psoriasis.1
How will brepocitinib cream compare with established treatments for mild-to-moderate eczema?
Stephanie J. Lax, Aaron M. Drucker
doi : 10.1111/bjd.21880
Brepocitinib (PF-06700841) is a small-molecule dual inhibitor of tyrosine kinase 2 and Janus kinase (JAK)1 previously administered orally in trials of other inflammatory dermatoses. In this issue of the BJD, Landis and coauthors report the results of a phase IIb study of brepocitinib cream vs. vehicle in mild-to-moderate eczema.1 Major advances have been made in the treatment of more severe eczema, with biologics and oral JAK inhibitors being approved in recent years.
Differences in cutaneous manifestations of COVID-19 during the Delta and Omicron waves revealed using the ZOE app
Mercè Grau-Pérez, Ignacio Garcia-Doval
doi : 10.1111/bjd.21868
Since the COVID-19 pandemic was declared, as of July 2022 over 565 million infections have been confirmed over the world,1 with different variants of the virus emerging in consecutive waves. Many of those variants have been classified at some point in time as ‘variants of concern’2 due to increased transmissibility or disease severity, the latest ones being Delta and Omicron.
Understanding the impact of life with vulval lichen sclerosus
Vanitha Sivalingam, Kajal Tamber
doi : 10.1111/bjd.21846
Vulval lichen sclerosis (VLS) is a chronic inflammatory condition of the anogenital skin with a preponderance in female patients. While prevalent in up to 3% of adult women, it remains an under-researched condition with limited understanding of its impact on quality of life. Traditional clinical guidance on vulval skin conditions, including lichen sclerosus from the British Association for Sexual Health and HIV1 and the British Association of Dermatologists,2 tends to focus on the clinical management and premalignant risk, with less emphasis on the psychosexual impact.
Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random
Hanjae Lee, Ohsang Kwon
doi : 10.1111/bjd.21838
The use of immune checkpoint inhibitors (ICIs) has increased exponentially in recent years for the treatment of various types of cancer. Notably, ICIs are associated with a large number of immune-related adverse events (irAEs), and cutaneous toxicities are among the most frequent adverse events experienced by patients treated with ICIs.1 A wide range of different skin toxicities can occur in these patients, which makes prompt recognition and adequate management of these symptoms difficult in the clinical setting.2
Follicular T helper cells and cutaneous T-cell lymphomas
Werner Kempf
doi : 10.1111/bjd.21839
Follicular T helper (TFH) cells are a subset of T cells that plays a crucial role for B cells in the formation of germinal centres and in homeostasis of immune responses.1 Phenotypically, TFH cells are characterized by the expression of programmed death (PD)-1, CXCL-13, inducible T-cell costimulator, bcl-6 and CD10.
Sensitization to epoxy resin systems in the wind turbine industry: an undesirable side-effect of renewable energies
Richard Brans
doi : 10.1111/bjd.21879
Epoxy resin systems are widely used as adhesives, sealants, inks, paints and coatings. Their components are well-known strong skin sensitizers and have become a major cause of allergic contact dermatitis in the construction industry in recent years.1
Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid
Khalaf Kridin, Christoph M. Hammers
doi : 10.1111/bjd.21882
The last two decades have witnessed a substantial increase in the incidence of bullous pemphigoid (BP) worldwide.1 One of the most compelling interpretations accounting for this epidemiological observation is the growing exposure to novel drug classes that might be implicated in eliciting the disease.1 Multiple lines of evidence have recently accumulated to suggest that exposure to dipeptidyl peptidase 4 (DPP4) inhibitors and checkpoint inhibitors (CPIs) is associated with an elevated risk of BP.2, 3 As these drugs were introduced only in the past two decades, their rising utilization underlies, at least in part, the growing incidence of BP.1
Transcriptomic analysis identifies regulators of the Wnt signalling and hypoxia-inducible factor pathways as possible mediators of androgenetic alopecia
Michael Philpott
doi : 10.1111/bjd.21881
While our understanding of the genetics of androgenetic alopecia has advanced rapidly,1 the molecular mechanisms are still poorly understood. This in part is due to samples of androgenetic alopecia scalp not being easy to obtain. Individuals with hair loss are not always keen to have scalp biopsies taken, and hair transplant technology has advanced such that punch biopsies are rarely taken from the balding site. This lack of material makes carrying out detailed investigation complicated. Moreover, the major mechanistic research focus over many years has been on the role of androgens.2
Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa*
Samar B. Hasan, Riham Gendra, JaBreia James, Delyth Morris, Lauren A.V. Orenstein, John R. Ingram
doi : 10.1111/bjd.21821
Pain is the most common and bothersome symptom experienced by people with hidradenitis suppurativa (HS) and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
Topical treatments in the management of keloids and hypertrophic scars: a critically appraised topic
Sina J. Ghadiri, Ewa Kloczko, Carsten Flohr
doi : 10.1111/bjd.21824
Topical treatments in the management of keloids and hypertrophic scars: a critically appraised topic
Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic
Andrew Affleck, David Jackson, Hywel C. Williams, Patricia Chavez, Joerg Albrecht
doi : 10.1111/bjd.21840
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)
Andrew Blauvelt, Alexa B. Kimball, Matthias Augustin, Yukari Okubo, Michael M. Witte, Claudia Rodriguez Capriles, Angelina Sontag, Vipin Arora, Olawale Osuntokun, Bruce Strober
doi : 10.1111/bjd.21743
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study*
Megan N. Landis, Mark Arya, Stacy Smith, Zoe Draelos, Lisa Usdan, Sanela Tarabar, Vivek Pradhan, Sudeepta Aggarwal, Christopher Banfield, Elena Peeva, Michael S. Vincent, Vanja Sikirica, Jason Xenakis, Jean S. Beebe
doi : 10.1111/bjd.21826
Atopic dermatitis (AD) is a prevalent inflammatory, pruritic skin disease. The Janus kinase (JAK) pathway is a treatment target.
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials*
Eric L. Simpson, Joseph F. Merola, Jonathan I. Silverberg, Kristian Reich, Richard B. Warren, Delphine Staumont-Sallé, Giampiero Girolomoni, Kim Papp, Marjolein de Bruin-Weller, Jacob P. Thyssen, Rebecca Zachariae, Christiana K. Olsen, Andreas Wollenberg
doi : 10.1111/bjd.21867
Tralokinumab is a fully human monoclonal antibody that neutralizes the activity of interleukin-13, a key pathogenic driver of atopic dermatitis (AD). Clinical trials including adults with moderate-to-severe AD, of up to 52 weeks’ duration, showed tralokinumab was efficacious and well tolerated.
Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app
Alessia Visconti, Benjamin Murray, Niccolò Rossi, Jonathan Wolf, Sebastien Ourselin, Tim D. Spector, Esther E. Freeman, Veronique Bataille, Mario Falchi
doi : 10.1111/bjd.21784
Symptoms of SARS-CoV-2 infection have differed during the different waves of the pandemic but little is known about how cutaneous manifestations have changed.
Living with vulval lichen sclerosus: a qualitative interview study*
Susanne Arnold, Sheryl Fernando, Sophie Rees
doi : 10.1111/bjd.21777
Vulval lichen sclerosus (VLS) is a chronic inflammatory condition predominantly affecting the anogenital skin. Symptoms can be distressing and affect quality of life and everyday activities. Very little research has been undertaken to explore the experience of living with VLS from the perspective of people with the condition.
Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study
Michaela Gabes, Aviël Ragamin, Arabella Baker, Gesina Kann, Theresa Donhauser, Daniela Gabes, Laura Howells, Kim S. Thomas, Jart A.F. Oosterhaven, Suzanne G.M.A. Pasmans, Marie L. Schuttelaar, Christian Apfelbacher
doi : 10.1111/bjd.21767
Recap of atopic eczema (RECAP) is a patient-reported outcome measure assessing eczema control. This instrument has been developed and validated in the UK. There are self-reported and proxy-reported versions in English, Dutch and German. However, it is unclear whether the self-reported version shows adequate content validity when completed by young people (8–16 years) in these languages.
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project*
Bria Midgette, Andrew Strunk, Oleg Akilov, Afsaneh Alavi, Christine Ardon, Falk G. Bechara, Arnon D. Cohen, Steven Cohen, Steven Daveluy, Véronique del Marmol, Maïa Delage, Solveig Esmann, Shani Fisher, Evangelos J. Giamarellos-Bourboulis, Amelia Glowaczewska, Noah Goldfarb, Elena Gonzalez Brant, Øystein Grimstad, Sandra Guilbault, Iltefat Hamzavi, Rosalind Hughes, John R. Ingram, Gregor B.E. Jemec, Qiang Ju, Naomi Kappe, Brian Kirby, Joslyn S. Kirby, Michelle A. Lowes, Lukasz Matusiak, Stella Micha, Robert Micheletti, Angela P. Miller, Dagfinn Moseng, Haley Naik, Aude Nassif, Georgios Nikolakis, So Yeon Paek, Jose Carlos Pascual, Errol Prens, Barry Resnik, Hassan Riad, Christopher Sayed, Saxon D. Smith, Yssra Soliman, Jacek C. Szepietowski, Jerry Tan, Linnea Thorlacius, Thrasyvoulos Tzellos, Hessel H. van der Zee, Bente Villumsen, Lanqi Wang, Christos Zouboulis, Amit Garg
doi : 10.1111/bjd.21798
Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored.
Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways
Qingmei Liu, Yulong Tang, Yan Huang, Ji’an Wang, Kai Yang, Yuting Zhang, Weilin Pu, Jing Liu, Xiangguang Shi, Yanyun Ma, Chunya Ni, Yue Zhang, Yifei Zhu, Haiyang Li, Jiucun Wang, Jinran Lin, Wenyu Wu
doi : 10.1111/bjd.21783
The key pathophysiological changes in androgenetic alopecia (AGA) are limited to hair follicles (HFs) in frontal and vertex regions, sparing the occipital region.
Germline intergenic duplications at Xq26.1 underlie Bazex–Dupré–Christol basal cell carcinoma susceptibility syndrome
Yanshan Liu, Siddharth Banka, Yingzhi Huang, Jonathan Hardman-Smart, Derek Pye, Antonio Torrelo, Glenda M. Beaman, Marcelo G. Kazanietz, Martin J. Baker, Carlo Ferrazzano, Chenfu Shi, Gisela Orozco, Stephen Eyre, Michel van Geel, Anette Bygum, Judith Fischer, Zosia Miedzybrodzka, Faris Abuzahra, Albert Rübben, Sara Cuvertino, Jamie M. Ellingford, Miriam J. Smith, D. Gareth Evans, Lizelotte J.M.T. Weppner-Parren, Maurice A.M. van Steensel, Iskander H. Chaudhary, D. Chas Mangham, John T. Lear, Ralf Paus, Jorge Frank, William G. Newman, Xue Zhang
doi : 10.1111/bjd.21842
Bazex–Dupré–Christol syndrome (BDCS; MIM301845) is a rare X-linked dominant genodermatosis characterized by follicular atrophoderma, congenital hypotrichosis and multiple basal cell carcinomas (BCCs). Previous studies have linked BDCS to an 11·4-Mb interval on chromosome Xq25-q27.1. However, the genetic mechanism of BDCS remains an open question.
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients
Vasiliki A. Nikolaou, Zoe Apalla, Cristina Carrera, Davide Fattore, Pietro Sollena, Julia Riganti, Sonia Segura, Azael Freites-Martinez, Konstantinos Lallas, Maria Concetta Romano, Chrysa Oikonomou, Michela Starace, Meletios A. Dimopoulos, Athanassios Kyrgidis, Elizabeth Lazaridou, Priscila Giavedoni, Maria Carmela Annunziata, Ketty Peris, Maria EcheverrÃÂa, Emilio Lopez-Tujillo, Konstandinos Syrigos, Chryssoula Papageorgiou, Sebastian Podlipnik, Gabriella Fabbrocini, Ana C. Torre, Christina Kemanetzi, Lorena Villa-Crespo, Aimilios Lallas, Alexander J. Stratigos, Vincent Sibaud
doi : 10.1111/bjd.21781
Cutaneous immune-related adverse events (irAEs) represent the most frequent toxicities induced by immune checkpoint inhibitors (ICIs).
Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study
Luojun Wang, Delphine Rocas, Stéphane Dalle, Nouhoum Sako, Laura Pelletier, Nadine Martin, Aurélie Dupuy, Nadia Tazi, Brigitte Balme, Béatrice Vergier, Marie Beylot-Barry, Agnès Carlotti, Martine Bagot, Maxime Battistella, Guillaume Chaby, Saskia Ingen-Housz-Oro, Philippe Gaulard, Nicolas Ortonne
doi : 10.1111/bjd.21791
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study*
Anusuya Kawsar, Charlotte Edwards, Pooja Patel, Richard M. Heywood, Aakriti Gupta, Jasmine Mann, Christopher Harland, Kara Heelan, James Larkin, Paul Lorigan, Catherine A. Harwood, Rubeta N. Matin, Louise Fearfield
doi : 10.1111/bjd.21836
Checkpoint inhibitor (CPI) therapy has significantly improved overall survival in several cancers including metastatic melanoma (MM) and in the adjuvant setting. Cutaneous immune-related adverse events (irAEs) secondary to CPIs are commonly observed; however, autoimmune blistering disorders such as bullous pemphigoid (BP) are rare.
Prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry
Alexandra G. Christiansen, Ole Carstensen, Mette Sommerlund, Per A. Clausen, Jakob H. Bønløkke, Vivi Schlünssen, Marléne Isaksson, Sigrun A. J. Schmidt, Henrik A. Kolstad
doi : 10.1111/bjd.21830
Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable
Anthony Dixon, Athanassios Kyrgidis, Christopher Zachary, John Dixon, Catalin Popescu, Michael Sladden, Zoe Apalla, Stuart Anderson, Giuseppe Argenziano, Demitrios Ioannides, Alexander Nirenberg, Aimillios Lallas, Samuel Zagarella, Caterina Longo, Harvey Smith, Howard Steinman, Thrasivoulos Tzellos, Lloyd Cleaver, Ken Leahey, Christos C. Zouboulis, J. Meirion Thomas
doi : 10.1111/bjd.21712
Safeguarding online research integrity: concerns from recent experience
Rachael M. Hewitt, Catherine Purcell, Chris Bundy
doi : 10.1111/bjd.21765
Where’s the colour? Advocating for morphological and antioppressive fluencies in dermatology
Gagandeep Singh, Onye Nnorom, Erin Dahlke
doi : 10.1111/bjd.21793
Dermatological considerations and culturally sensitive recommendations for women who wear the hijab
Rafey Rehman, Mahfujul Haque, Marissa Ceresnie, Iltefat H. Hamzavi, Fatima Fahs, Tasneem F. Mohammad
doi : 10.1111/bjd.21795
Currently, there is little guidance in the literature on how to advise patients who wear the hijab on hijab-related dermatoses. This manuscript describes hijab-related dermatoses and provides culturally sensitive recommendations that can be used in conjunction with standard treatments to provide more holistic care for these patients.
The sound of silence: where are the voices of patients in eczema guideline development?
Korey Capozza, Anne Vastrup, Andrew Proctor, Amanda Roberts, Mario Picozza, Rachael Manion, Cheryl Talent, Marjolaine Hering, Stephanie Merhand, Melanie Funk, Kathryn Z. Tullos, Bernd W.M. Arents
doi : 10.1111/bjd.21822
Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization
Ulrich Mrowietz, Matthias Augustin
doi : 10.1111/bjd.21827
Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome
Claire Laurent, Guillaume Lefèvre, Jean-Emmanuel Kahn, Delphine Staumont-Salle, Renaud Felten, Marie Puget, Thomas Moulinet, Irène Machelart, David Launay, Estelle Charvet, Jean David Bouaziz, Marie Jachiet, Alexandra Espitia, Alfred Mahr, Christian Le Clech, Marion Malphettes, Cécile Morice, Samia Mourah, Hélène Moins-Teisserenc, François Lifermann, Karine Soulier-Guérin, Alban Villate, Chloé Baillou, Aurélie Grados, Ailsa Robbins, Noemie Abisror, Martine Bagot, David Boutboul, Kewin Panel, Marie-Dominique Vignon-Pennamen, Jacqueline Rivet, Maxime Battistella, Matthieu Groh, Adèle de Masson, on behalf of the CEREO network
doi : 10.1111/bjd.21782
Psychosocial burden of frontal fibrosing alopecia: a qualitative interview study
Madison K. Cook, Patrick O. Perche, Jonathan C. White, Steven R. Feldman, Lindsay C. Strowd
doi : 10.1111/bjd.21786
Low predictive value of questionnaire-based diagnosis of hidradenitis suppurativa
Jonathan Koptyev, Andrew Strunk, Amit Garg
doi : 10.1111/bjd.21787
Nailfold videocapillaroscopy and serum vascular endothelial growth factor in probable COVID-19-induced chilblains: a cross-sectional study to assess microvascular impairment
Yora Mostmans, Vanessa Smith, Maurizio Cutolo, Karin Melsens, Salomé Battist, Asma Benslimane, Francis Corazza, Bertrand Richert, Olivier Michel, Athanassios Kolivras
doi : 10.1111/bjd.21785
Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin
Gabriele Roccuzzo, Paolo Fava, Gianluca Avallone, Carola Aquino, Sara Boskovic, Nicole Macagno, Simone Ribero, Pietro Quaglino
doi : 10.1111/bjd.21772
Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry
Dora Stölzl, Nicole Sander, Annice Heratizadeh, Eva Haufe, Inken Harder, Susanne Abraham, Luise Heinrich, Andreas Kleinheinz, Andreas Wollenberg, Elke Weisshaar, Knut Schäkel, Konstantin Ertner, Franca Wiemers, Julia Wildberger, Margitta Worm, Ralph von Kiedrowski, Isaak Effendy, Andrea Asmussen, Matthias Augustin, Mario Pawlak, Michael Sticherling, Alexander Zink, Melanie Hilgers, Christiane Handrick, Sven Quist, Beate Schwarz, Petra Staubach-Renz, Magnus Bell, Sun-Hei Hong-Weldemann, Bernhard Homey, Jens-Joachim Brücher, Jochen Schmitt, Thomas Werfel, Stephan Weidinger, the TREATgermany study group
doi : 10.1111/bjd.21794
Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris
Antonio Ji-Xu, Donald K. Lei, Scott Worswick, Nolan J. Maloney, Mindy M. Kim, Lauren Cutler
doi : 10.1111/bjd.21792
Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association
Bruno Matard, Emmanuelle Bourrat, Marine Cavalié, Christine Chiaverini, Pascal Reygagne
doi : 10.1111/bjd.21796
This work reports 30 cases of folliculitis decalvans (FD) in patients with dystrophic epidermolysis bullosa (DEB) among a cohort of 125 DEB patients seen between 2010 and 2021 in 2 French expert centers for the management of inherited epidermolysis bullosa. Such an association between two rare diseases cannot be fortuitous and implies a physiopathological link that we discuss in this paper. This association is a new significant fact to add to the reflexion on FD causes, suggesting that skin abnormality of DEB could act as a factor of a specific skin barrier alteration which could favor FD. Scarring alopecia with tufted folliculitis and pustules on inflamed skin at the vertex of a woman with dominant dystrophic epidermolysis bullosa.
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
Lara S. van der Schoot, Selma Atalay, Marisol E. Otero, Wietske Kievit, Juul M.P.A. van den Reek, Elke M.G.J. de Jong
doi : 10.1111/bjd.21797
Lichen sclerosus in female patients is associated with an increased risk of metabolic syndrome and cardiovascular comorbidities: a retrospective cohort review
Alison Ranum, Rebecca Freese, Vidhyalakshmi Ramesh, David R. Pearson
doi : 10.1111/bjd.21811
COVID-19 pandemic-associated chilblains: more links for SARS-CoV-2 and less evidence for high interferon type I systemic response
Didier Bessis, Sophie Trouillet-Assant, Léo-Paul Secco, Nathalie Bardin, Brigitte Blanc, Véronique Blatière, Christine Chable-Bessia, Christophe Delfour, Céline Girard, Jean-Christophe Richard, Nathalie Gros, Vincent Le Moing, Nicolas Molinari, Valérie Pallure, Amandine Pisoni, Nadia Raison-Peyron, Elisa Reynaud, Émilie Schwob, Rémi Pescarmona, Quentin Samaran, Marjolaine Willems, Thierry Vincent, Mircea T. Sofonea, Alexandre Belot, Édouard Tuaillon
doi : 10.1111/bjd.21820
A qualitative study of patients’ experiences of screening for psoriatic arthritis
Christine A. Silverthorne, Clive Bowen, Jane Lord, Neil McHugh, William Tillett, Emma Dures, Anya Lissina
doi : 10.1111/bjd.21825
Progression of in situ and early invasive cutaneous squamous cell carcinomas concurrent with successful target tumour response to a programmed death-1 inhibitor
Kelly McCoy, Jennifer DeSimone
doi : 10.1111/bjd.21831
Dear Editor, The treatment of locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC) is challenging. In many cases, the burden of disease is beyond what can be managed with surgery and radiation therapy. The medical management of unresectable tumours has historically defaulted to head and neck SCC protocols,1 resulting in unfavourable outcomes.
Qualitative analysis of the impact of atopic dermatitis on caregivers
Richard W. Kim, Kelly Barta, Wendy S. Begolka, Korey Capozza, Sanaz Eftekhari, Kathryn Tullos, Natalie Tomaszewski, Claire Snell-Rood, Katrina Abuabara
doi : 10.1111/bjd.21828
The quantitative impact of atopic dermatitis on caregivers across multiple life domains
Richard W. Kim, Kelly Barta, Wendy S. Begolka, Korey Capozza, Sanaz Eftekhari, Kathryn Tullos, Natalie Tomaszewski, Claire Snell-Rood, Katrina Abuabara
doi : 10.1111/bjd.21855
Three new founder mutations in Chinese patients with Nagashima-type palmoplantar keratoderma
Juan Liu, Zhiming Chen, Linghan Hu, Zhongya Song, Ran Mo, Lemuel Shui-Lun Tsang, Yihe Liu, Xin Huang, Zhuoqing Gong, Ruiyu Xiang, Zhimiao Lin, Yong Yang
doi : 10.1111/bjd.21835
A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation
Mathilde C.S.C. Vermeer, Mohammad Al-Shinnag, Herman H.W. Silljé, Antonio Esquivel Gaytan, Dedee F. Murrell, Julie McGaughran, Wei Melbourne, Timothy Cowan, Peter C. van den Akker, Karin Y. van Spaendonck-Zwarts, Peter van der Meer, Maria C. Bolling
doi : 10.1111/bjd.21832
This study shows that gain-of-function variants in KLHL24 causing EBS and DCM, do not only originate in the start-codon and suggest that any nonsense-inducing variant affecting nucleotides c.4_84 will likely cause the same effect on protein level and a similar potential lethal phenotype.
Plasma cells and acute rejection of a near-total face transplant: an incidental finding or an evolving plasma-cell-mediated rejection?
Rebecca Knackstedt, Wilma Bergfeld, Luis Antonio Sardiña, Bijan Eghtesad, Maria Siemionow, Risal Djohan
doi : 10.1111/bjd.21823
Monkeypox: a new differential diagnosis when addressing genital ulcer disease
Joseph Griffiths-Acha, Miguel Vela-Ganuza, Claudia Sarró-Fuente, José Luis López-Estebaranz
doi : 10.1111/bjd.21834
We describe a case of genital ulcer and inguinal adenopathies that were attributable to monkeypox virus infection. We suggest clinicians adopt a low threshold for suspicion, particularly when evaluating genital ulcer disease.
Giant congenital melanocytic naevus with a novel CUX1–BRAF fusion mutation treated with trametinib
Vered Molho-Pessach, Stav Hartshtark, Sharon Merims, Michal Lotem, Nadia Caplan, Hila Alfassi, Alex Maly, Gal Goldstein, Rakefet Sidlik Muskatel
doi : 10.1111/bjd.21851
Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey
Britney N. Wilson, Rohan Shah, Christian Menzer, Abdullah Aleisa, Mary D. Sun, Bernice Y. Kwong, Ben H. Kaffenberger, Lucia Seminario-Vidal, Christopher A. Barker, Michael D. Stubblefield, Paul B. Romesser, Gabriella Fabbrocini, Murad Alam, Farah Abdulla, Brittany Dulmage, Vincent Sibaud, Milan Anadkat, Jean-Michel Mazer, Dhwani Parikh, Beth McLellan, Hugues Cartier, Silvina Pugliese, Albert Wolkerstorfer, Hans-Joachim Laubach, Nicole LeBoeuf, Jonathan Leventhal, Derrick C. Wan, Jennifer Choi, Thanh Nga Tran, R. Rox Anderson, Alina Markova, Anthony Rossi
doi : 10.1111/bjd.21852
On the potential beneficial effects of indoor tanning
Pelle G. Lindqvist, Elisabeth Epstein, Mona Landin-Olsson
doi : 10.1111/bjd.21829
Dear Editor, We read with great interest the article by Eden et al.1 entitled ‘Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning’, concluding that banning of indoor tanning would save lives.
On the potential beneficial effects of indoor tanning: reply from the authors
Martin Eden, Rob Hainsworth, Louisa G. Gordon, Tracy Epton, Paul Lorigan, Lesley E. Rhodes, Richard Marais, Adele C. Green, Katherine Payne
doi : 10.1111/bjd.21854
Response to ‘Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable’
Mark B. Faries, Alistair J. Cochran, John F. Thompson
doi : 10.1111/bjd.21841
Dear Editor, A recent Perspectives article in the BJD1 suggested that the first Multicenter Selective Lymphadenectomy Trial (MSLT-1),2 though ‘seminal’, required additional reporting. Although MSLT-1 completed accrual more than two decades ago and results have been published in eight prior peer-reviewed manuscripts, we are pleased to provide additional relevant information.
Atezolizumab-induced linear IgA bullous dermatosis
Silvia Aguilar-Duran, John Mee, Sanjay Popat, Kara Heelan
doi : 10.1111/bjd.21653
A monkeypox virus infection mimicking primary syphilis
Martina Turco, Fabrizio R. Mancuso, Luigi Pisano
doi : 10.1111/bjd.21847
Given the current monkeypox virus (MPXV) outbreak in at-risk men who have sex with men (MSM), clinicians should consider MPXV a differential diagnosis of syphilis, in any patient with a solitary painless genital nodule.
A review of how pain is measured in painful skin conditions and rheumatoid arthritis studies, to determine pain measurement in future hidradenitis suppurativa trials
doi : 10.1111/bjd.21885
Hidradenitis suppurativa (HS) is an inflammatory skin condition that causes boils, abscesses and skin tunnels in areas where there are creases in the skin. Pain is the most common symptom experienced by people with HS.
Skin reactions to immune checkpoint inhibitors used in cancer treatment
doi : 10.1111/bjd.21886
Immune checkpoint inhibitors (ICIs, such as ipilimumab and pembrolizumab) are drugs used in the late stages of some cancers, including melanoma, kidney cancer and non-small cell lung cancer. ICIs act by enhancing a person’s immune defence against the cancer. Unfortunately, adverse effects on the immune system are common, affecting around 60% of patients. Skin reactions are especially frequent, requiring treatment to be interrupted or even discontinued.
Insights into the biological differences in hair follicles of men with androgenetic alopecia
doi : 10.1111/bjd.21887
Androgenetic alopecia (AGA) is a condition that leads to balding, mainly of the front and top of the head. AGA affects around half of all men worldwide and can have a great impact on their appearance and social life.
The effectiveness and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis
doi : 10.1111/bjd.21889
Atopic dermatitis (AD) is a common skin disease that causes patches of dry and itchy skin. Despite current treatments there is still a need for safe and effective topical therapies to improve disease management and long-term outcomes for patients with mild-to-moderate AD.
Blistering skin side-effects associated with checkpoint inhibitor treatment for cancer
doi : 10.1111/bjd.21890
Checkpoint inhibitors (CPIs) are new types of treatments that have been shown to be effective against several cancers by boosting a person’s immune system to fight off the underlying cancer. CPIs have significantly improved the overall survival of people diagnosed with cancer. However, skin-related side-effects of CPIs are common (up to 49%), although more severe reactions such as blistering conditions, for example bullous pemphigoid, are rare.
Safety of tralokinumab for the treatment of atopic dermatitis
doi : 10.1111/bjd.21891
Tralokinumab is a new biologic drug, known as a monoclonal antibody. This is a manufactured antibody designed to block a specific section of the immune system, which in this case is a substance called interleukin-13. This interleukin plays a key role in causing the inflammation involved in atopic dermatitis.
Patient experiences of living with vulval lichen sclerosus
doi : 10.1111/bjd.21892
Vulval lichen sclerosus (VLS) is a chronic inflammatory condition mostly affecting anogenital skin. Symptoms of VLS can be distressing and can have a huge impact on everyday life. Despite this there is very little research exploring the experiences of people living with the condition.
Skin-related symptoms found in people with COVID-19 during the Delta and Omicron waves
doi : 10.1111/bjd.21893
Individuals infected with COVID-19 sometimes experience unusual skin rashes such as urticarial rash, a chickenpox-type rash, and reddish and purplish bumps on the fingers or toes (sometimes known as ‘COVID toes’) as well as other rarer skin-related changes. Symptoms of COVID-19 have changed during the different waves of infection, and little is known about how these skin-related symptoms have changed.
Patient satisfaction with treatment for hidradenitis suppurativa
doi : 10.1111/bjd.21894
Hidradenitis suppurativa (HS) is a long-term, recurrent and painful disease where there is inflammation (tenderness and swelling) in the armpits, breasts and groin. Nearly half of patients with HS report dissatisfaction with their treatment. However, there is little research exploring which factors are associated with patient satisfaction.
The effectiveness and safety of mirikizumab for treatment of psoriasis
doi : 10.1111/bjd.21895
Plaque psoriasis is a common skin disease that affects about 125 million people worldwide. The condition is caused by an overactive immune system resulting in raised, scaly and itchy patches on the skin (called plaques). Plaques can be extensive and appear anywhere on the body, or can be limited to a few areas. Most patients require treatment over a long period of time.
The genetic cause of a rare skin cancer syndrome, Bazex–Dupré–Christol syndrome
doi : 10.1111/bjd.21897
Bazex–Dupré–Christol syndrome (BDCS) is a rare genetic skin condition characterized by poor hair growth, prominent hair follicle openings, especially on the backs of the hands, and multiple skin tumours, particularly basal cell carcinomas (BCCs).
Skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry
doi : 10.1111/bjd.21898
Epoxy products are widely used as components of protective surfaces, adhesives, paints and in the manufacturing of wind turbines. They are a common cause of allergic contact dermatitis, involving an eczema reaction when the skin comes into contact with an allergen (such as epoxy) causing sensitization.
Skin lymphomas of the T-follicular helper type
doi : 10.1111/bjd.21899
There is a group of lymphomas (cancer from immune system cells) in the skin made of neoplastic cells resembling T-follicular helper (TFH) cells (a very specific subtype of immune cell). These lymphomas are rare and poorly described to date, and there is no standard treatment for them. These lymphomas do not appear to fit with other established types of lymphoma, either in the skin or elsewhere in the body.
关于如何在疼痛性皮肤病和类风湿关节炎ç â€�究ä¸Â测é‡Â�疼痛，以确定未æÂ�¥åŒ–脓性汗腺炎试验ä¸Â的疼痛测é‡Â�的综述
doi : 10.1111/bjd.21900
化脓性汗腺炎 (HS) 是一�炎症性皮肤病，会在皮肤有褶皱的部�引起疖�脓肿和皮肤隧�。疼痛是 HS 患者最常�的症状。
对癌症治疗ä¸Â使çâ€�¨çš„å…Â�疫检查点抑制剂的皮肤åÂ�Â�åºâ€�
doi : 10.1111/bjd.21901
å…Â�疫检查点抑制剂(ICI，如伊匹木åÂ�•æŠ—和帕åÂ�šåˆ©çÂ� åÂ�•æŠ—)是çâ€�¨äºŽæŸÂ�些晚期癌症的èÂ�¯ç‰©ï¼ŒåŒ…括黑色素瘤ã€Â�肾癌和éÂ�žå°Â�细胞肺癌。ICI 的作çâ€�¨æ˜¯å¢žå¼ºäººä½“对癌症的å…Â�疫防御。éÂ�—憾的是，ICI 对å…Â�疫系统的ä¸Â�良åÂ�Â�åºâ€�很常è§Â�，大约 60% 的患者会åÂ�—æ¤影å“Â�。皮肤åÂ�Â�åºâ€�尤其频ç¹Â�，需è¦Â�ä¸Âæ–Âçâ€�šè‡³åÂ�Ͼ¢治疗。
对雄激素性脱åÂ�‘çâ€�·æ€§æ¯›å›Šçâ€�ٍ䩌¦差异的è§Â�解
doi : 10.1111/bjd.21902
雄激素性脱� (AGA) 是一�导致秃顶的疾病，主���在头部的�部和顶部。全世界大约一�的�性患 AGA，并�这会对他们的外表和社交�活产�巨大影�。
外çâ€�¨ Brepocitinib 治疗轻ä¸Â度特åºâ€�性皮炎的有效性和安全性
doi : 10.1111/bjd.21903
特åºâ€�性皮炎 (AD) 是一ç§Â�常è§Â�的皮肤病，会导致皮肤干燥和åÂ�‘痒。尽管目å‰Â�有治疗方法，但ä»Â�需è¦Â�安全有效的外çâ€�¨æ²»ç–—，以æâ€�¹å–„轻度至ä¸Â度 AD 患者的疾病管çÂ�†å’Œé•¿æœŸé¢„åÂ�Žã€‚
与癌症检查点抑制剂治疗相关的皮肤水疱副作�
doi : 10.1111/bjd.21904
检查点抑制剂 (CPI) 是一ç§Â�新型治疗方法，已被è¯Â�明åÂ�¯é€šè¿‡å¢žå¼ºäººä½“å…Â�疫系统æÂ�¥å¯¹æŠ—潜在癌症，从而有效治疗多ç§Â�癌症。CPI 显著æÂ�Â�高了癌症确诊患者的总çâ€�Ÿå˜率。然而，CPI 的皮肤相关副作çâ€�¨å¾ˆå¸¸è§Â�(高达 49%)，尽管更严é‡Â�çš„åÂ�Â�åºâ€�(例如水疱状况，如大疱性类天疱疮)很少è§Â�。
曲罗芦�抗治疗特�性皮炎的安全性
doi : 10.1111/bjd.21905
曲罗芦åÂ�•æŠ—是一ç§Â�æ–°çš„çâ€�ٍ䩏Â�¯ç‰©ï¼Œè¢«ç§°ä¸ºåÂ�•å…‹éš†æŠ—体。çâ€�Ÿäº§è¯¥æŠ—体旨在阻æ–Âå…Â�疫系统的特定部分，åÂ�³ä¸€ç§Â�被称为白细胞介素13 的物质。这ç§Â�白细胞介素在引起与特åºâ€�性皮炎有关的炎症ä¸Âèµ·å…³éâ€�®ä½œçâ€�¨ã€‚
外阴硬化性�藓患者的疾病体验
doi : 10.1111/bjd.21906
外阴硬化性è‹â€�è—“ (VLS) 是一ç§Â�慢性炎症性疾病，主è¦Â�å½±å“Â�肛门çâ€�Ÿæ®–器皮肤。VLS 的症状åÂ�¯èƒ½ä»¤äººç—›è‹¦ï¼Œå¹¶å¯¹æ—¥å¸¸çâ€�Ÿæ´»äº§çâ€�Ÿå·¨å¤§å½±å“Â�。尽管如æ¤，很少有ç â€�究探索患有这ç§Â�疾病的患者的体验。
在德å°â€�å¡â€�和奥密克戎疫情波次期间在新冠肺炎患者ä¸ÂÃ¥Â�‘现的皮肤相关症状
doi : 10.1111/bjd.21907
感染新冠肺炎的患者有时会出现ä¸Â�寻常的皮疹，例如èÂ�¨éº»ç–¹ã€Â�水痘型皮疹ã€Â�手指或脚趾红色和紫色肿åÂ�— (有时称为“COVID 脚趾â€Â�) 以åÂ�Šå…¶ä»–罕è§Â�的皮肤相关åÂ�˜åŒ–。新冠肺炎的症状在ä¸Â�​​åÂ�Œçš„感染波次ä¸ÂÃ¥Â�‘çâ€�ŸåÂ�˜åŒ–，而对于这些与皮肤相关的症状是如何åÂ�˜åŒ–çš„åÂ�´çŸ¥ä¹‹çâ€�šå°‘。
患者对化脓性汗腺炎治疗的满�度
doi : 10.1111/bjd.21908
化脓性汗腺炎 (HS) 是一�长期���和疼痛性疾病，患者的腋��乳房和腹股沟出现炎症(压痛和肿胀)。近一�的 HS 患者报告对他们的治疗�满�。然而，很少有�究探索哪些因素与患者满�度相关。
Mirikizumab 治疗银屑病的有效性和安全性
doi : 10.1111/bjd.21909
斑�状银屑病是一�常�的皮肤病，影�全�约 1.25 亿人。这�疾病是�过度活跃的�疫系统引起的，导致皮肤上出现凸起�鳞屑和�痒性斑片(称为斑�)。斑��以很广泛，出现在身体的任何部�，也�以仅局�于少数区域。大多数患者需�长期治疗。
罕è§Â�皮肤癌综åÂ�ˆå¾Â�: Bazex-Dupré-Christol 综åÂ�ˆå¾Â�çš„éÂ�—传原å›Â
doi : 10.1111/bjd.21910
Bazex-Dupré-Christol 综åÂ�ˆå¾Â� (BDCS) 是一ç§Â�罕è§Â�çš„éÂ�—传性皮肤病，其特å¾Â�是毛åÂ�‘çâ€�Ÿé•¿ä¸Â�良ã€Â�毛囊åÂ�£çªÂ�出，尤其是手背，以åÂ�Šå¤šåÂ�‘性皮肤肿瘤，尤其是基底细胞癌 (BCC)。BDCS 是一ç§Â� X è¿žéâ€�Â�显性éÂ�—传病，这æ„Â�味çÂ�یÂ�—å½±å“Â�的父亲会将这ç§Â�疾病éÂ�—传给他的女儿，但ä¸Â�会éÂ�—传给儿åÂÂ�，而åÂ�—å½±å“Â�çš„æ¯Â�亲有 50% 的机会将这ç§Â�疾病éÂ�—传给她的儿åÂÂ�和女儿。既往ç â€�究已ç»Â�确定 X 染色体长臂上的一个区域，称为 Xq25-q27·1。它åÂ�«æœ‰åŸºå› ACTRT1，怀疑其会导致 BDCS。
风力涡轮机行业暴露于环氧树脂的工人的皮肤过�和皮炎
doi : 10.1111/bjd.21911
环氧树脂产å“Â�广泛çâ€�¨ä½œä¿Â�护表éÂ�¢ã€Â�粘åÂ�ˆå‰‚ã€Â�油漆和风力涡轮机çâ€�Ÿäº§çš„组件。它们是过æ•Â�性接触性皮炎的常è§Â�原因，当皮肤接触过æ•Â�原(如环氧树脂)时会引起湿疹åÂ�Â�åºâ€�，从而引起过æ•Â�。斑贴试验是çâ€�¨äºŽè¯Šæ–Â皮肤过æ•Â�的方法，通过将目标过æ•Â�原贴敷在皮肤上，观察是åÂ�¦ä¼šè§¦åÂ�‘åÂ�Â�åºâ€�。在风力涡轮机行业，估计有 11% 的工人对环氧树脂æ•Â�感。
T 滤泡辅助型皮肤淋巴瘤
doi : 10.1111/bjd.21912
皮肤ä¸Â有一组淋巴瘤(æÂ�¥è‡ªå…Â�疫系统细胞的癌症)，其çâ€�±ç±»ä¼¼äºŽ T 滤泡辅助 (TFH) 细胞(一ç§Â�éÂ�žå¸¸ç‰¹æ®Šçš„å…Â�疫细胞亚型)的肿瘤细胞组æˆÂ�。这些淋巴瘤很少è§Â�，迄今为æ¢对其æÂ�Â�述很少，并ä¸â€�没有针对它们的标准治疗方法。这些淋巴瘤的特点似乎ä¸Â�符åÂ�ˆå…¶ä»–已确定类型的淋巴瘤(无论是在皮肤还是身体其他部ä½Â�)。
